靈敏可靠的Bradykinin ELISA kit——ENZO熱銷產(chǎn)品

靈敏可靠的ELISA試劑盒，用于檢測(cè)血漿、血清和尿液樣本中的緩激肽

緩激肽（Bradykinin）于1949年被發(fā)現(xiàn)，由血漿中的球蛋白前體在蛋白酶的作用下生成。它的名字表明它會(huì)促使腸道緩慢運(yùn)動(dòng)。早在1909年，人們就注意到在尿液中發(fā)現(xiàn)的物質(zhì)（后來(lái)被確定為激肽）具有降壓作用。激肽是血管舒張、血管通透性、NO 釋放和花生四烯酸動(dòng)員的效應(yīng)物。它們是血壓、腎功能和心臟功能的重要調(diào)節(jié)因子，并且還參與炎癥反應(yīng)。

緩激肽是通過(guò)血液中激肽釋放酶系統(tǒng)的作用（與凝血級(jí)聯(lián)有關(guān)）從血球蛋白激肽原HK 產(chǎn)生的，但也可以在其他組織和器官中產(chǎn)生。除激肽釋放酶外，其他蛋白酶如纖溶酶也可釋放緩激肽。幾種肽酶可以降解激肽，包括血管緊張素轉(zhuǎn)化酶(ACE)，這是一種可將血管緊張素 I 轉(zhuǎn)化為血管緊張素 II 并破壞緩激肽的金屬蛋白酶。血漿緩激肽迅速降解為較小的穩(wěn)定肽(BK1-5)形式。

Enzo Life Sciences/欣博盛生物 的緩激肽（Bradykinin）ELISA試劑盒是一種競(jìng)爭(zhēng)比色法免疫檢測(cè)試劑盒，可在3小時(shí)內(nèi)得出結(jié)果。欣博盛生物作為Enzo Life Sciences授權(quán)中國(guó)一級(jí)代理，可提供該產(chǎn)品，歡迎咨詢。

產(chǎn)品特點(diǎn)

◆ 靈敏、可靠地檢測(cè)低至 24.8 pg/ml 的緩激肽

◆ 僅需3小時(shí)即可得到多達(dá) 41 個(gè)樣本（帶復(fù)孔）的實(shí)驗(yàn)結(jié)果

◆ 動(dòng)態(tài)范圍寬，可輕松量化高表達(dá)水平和低表達(dá)水平的緩激肽

◆ 易于使用的液體顏色編碼試劑，可減少錯(cuò)誤

產(chǎn)品信息

標(biāo)準(zhǔn)曲線示例

部分產(chǎn)品引用文獻(xiàn)

Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe CO'VID-19: C.P. Martens, et al.; EBioMedicine 83, 104195 (2022)

Activation of angiotensin type 2 receptor attenuates testosterone-induced hypertension and uterine vascular resistance in pregnant rats: J.S. Mishra & S. Kumar; Biol. Reprod. 2021, ioab051 (2021)

gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema: M. Fandaros, et al.; Inflammation 1007, 10753 (2021)

Plasma contact factors as novel biomarkers for diagnosing Alzheimer's disease: J. Park, et al.; Biomark. Res. 9, 5 (2021)

The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome: M. Punapart, et al.; Genes (Basel) 12, 1717 (2021)

An antibody against HK blocks Alzheimer's disease peptide β-amyloid-induced bradykinin release in human plasma: Z.L. Chen, et al.; PNAS 116, 22921 (2019)

Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2: Y. Zhou, et al.; Int. J. Oncol. 55, 131 (2019)

Post-translational modifications of eNOS augment nitric oxide availability and facilitates hypoxia adaptation in Ladakhi women: Pooja, et al.; Nitric Oxide 78, 103 (2018)

Protocols to assess coagulation following in vitro infection with hemorrhagic fever viruses: M.L. Tursiella, et al.; Methods Mol. Biol. 1604, 405 (2018)

Intestinal ischemic preconditioning ameliorates hepatic ischemia/reperfusion injury in rats: role of heme oxygenase 1 in the second window of protection: S. Kageyama, et al.; Liver Transpl. 21, 112 (2015)

Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction: J. Flores-Monroy, et al.; Pharmacology 94, 21 (2014)

High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis: A. Yang, et al.; J. Immunol. 192, 4398 (2014)

詳情請(qǐng)聯(lián)系 ENZO 金牌代理商-欣博盛生物